RNA | Avidity Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	30.40 - 31.68
52 Week Range	9.93 - 56.00
Beta	1.19
Implied Volatility	57.18%
IV Rank	16.43%
Day's Volume	986,181
Average Volume	1,106,911
Shares Outstanding	119,309,000
Market Cap	3,673,524,110
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-12

Valuation
Profitability
Growth
Health
P/E Ratio	-10.69
Forward P/E Ratio	N/A
EPS	-2.88
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	253
Country	USA
Website	RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA's peers: ADCT, AKRO, CLDX, DNLI, IDYA, IGMS, INSM, MDWD, OMER, PTGX, QSI, QURE, RGNX, TCRR, RVMD, BDTX, BCEL, PASG, STOK, CERE, CGEM, MLYS, DAWN, SWTX, RLAY, PLRX, ARVN, RYTM, SLN, SRRK, TVTX, UBX

*Chart delayed

Analyzing fundamentals for RNA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see RNA Fundamentals page.

Watching at RNA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RNA Technicals page.